

Dear Dr Longson

**Single technology appraisal (STA)
Erlotinib monotherapy for the maintenance treatment of non-small cell lung
cancer**

Thank you for the opportunity to comment on this ACD. BTOG members have been consulted by email on this matter. The replies received were unanimously positive and supportive of this ACD and therefore BTOG does not have any further comments.

Yours sincerely



For and on behalf of

British Thoracic Oncology Group (BTOG)